First Biosimilar to the Original Erbitux Enters the Market

R-Pharm's EGFR-targeted biosimilar, Arcetux (RPH-002), has successfully completed its Phase 3 clinical trial and received official marketing authorization from the Ministry of Health of the Russian Federation. This marks a significant milestone in the biopharmaceutical industry as it is the world's first biosimilar to be registered for Erbitux (cetuximab), which is marketed by Merck KGaA and Eli Lilly. Erbitux has been a cornerstone in the treatment of unresectable, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC); however, its high cost has created a significant financial burden for patients. This approval is expected to trigger price competition in the global biosimilar market, starting with the Russian market, and significantly improve patient access to treatment.

Demonstrated Equivalence and Safety in Phase 3 Clinical Trial

The Phase 3 clinical trial, which served as the basis for this approval, involved more than 250 patients with unresectable, recurrent, or metastatic HNSCC who received docetaxel and cisplatin combination therapy as a first-line treatment. The researchers directly compared the efficacy, immunogenicity, and safety profile of the original Erbitux and Arcetux, demonstrating complete therapeutic equivalence. The mechanism of action, which selectively inhibits EGFR to block the proliferation of tumor cells, was found to be no different from the original, increasing confidence in its clinical use. In particular, the consistent immunogenicity data is expected to serve as a strong regulatory tool to offset potential adverse effects during the switching process.

Addressing Unmet Needs in the Head and Neck Cancer Market

HNSCC is a high-risk malignancy that occurs in the mucosal tissues of the head and neck, such as the mouth and pharynx. It is difficult to detect early and has a high recurrence rate, resulting in a very poor prognosis. While immune checkpoint inhibitors, such as pembrolizumab, have emerged as standard treatments, EGFR-targeted antibody therapies remain the only alternative for patients with PD-L1-negative or immune checkpoint inhibitor-ineligible tumors. Arcetux provides an effective solution for this target patient population, offering the same efficacy as the original while significantly reducing treatment costs. It also offers humanitarian value by providing patients who could not afford treatment with a real opportunity to extend their lives.

Strategic Value in the Russian Healthcare Market

Upon approval, Arcetux was immediately listed on the Vital and Essential Drugs (VED) list designated by the Russian government, making it a key tool for maximizing the efficiency of the national healthcare budget. The Russian government can now reduce national healthcare spending by replacing expensive imported drugs with domestically produced biosimilars and provide high-quality targeted therapies to its patients in a stable manner. This is also in line with the government's strategy to secure a stable healthcare supply chain in the face of supply chain issues and geopolitical risks from multinational pharmaceutical companies. R-Pharm is expected to leverage this VED listing to quickly dominate the bidding market in public and private hospitals across Russia.